ArticleSurgery today2025
Impact of adjuvant chemotherapy on survival outcomes in older and non-older patients with high-risk stage II colorectal cancer.
Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the impact of adjuvant chemotherapy on oncological outcomes in older and non-older patients with high-risk stage II colorectal cancer (CRC).
methodsWe retrospectively analyzed 247 patients diagnosed between January 2014 and August 2023. Clinicopathological factors, adjuvant chemotherapy, and the 3-year recurrence-free survival (3y-RFS) and overall survival (3y-OS) were analyzed. Older patients were defined as those ≥ 70 years old.
resultsOf 247 patients, 154 (62.3%) were older. Adjuvant chemotherapy rates were significantly lower in older patients than in non-older ones (29.2% vs. 51.6%, p < 0.001). Side effects were the primary cause of discontinuation. The 3y-RFS improved with chemotherapy completion (non-older: 96.3% vs. 82.7%, p = 0.053; older: 100.0% vs. 83.7%. p = 0.028). Similarly, the 3y-OS also increased with chemotherapy completion (non-older: 100.0% vs. 91.9%, p = 0.475; older: 100.0% vs. 93.2%, p = 0.0139). A multivariate analysis identified obstruction (hazard ratio [HR], 4.153; p < 0.001), pT4 (HR, 3.891; p = 0.003), and adjuvant chemotherapy completion (HR, 0.046; p = 0.009) as independent RFS predictors.
conclusionsOlder patients were less likely to receive adjuvant chemotherapy than non-older ones primarily due to adverse effects. The completion of adjuvant chemotherapy notably improved the prognosis of high-risk stage II colorectal cancer. Patients with pT4 or obstruction have a poor prognosis, and the completion of adjuvant chemotherapy with appropriate management of adverse effects may improve the prognosis.
Indexed as
Identifiers
40524028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.